Madison, WI, April 3, 2018– Today Imbed Biosciences, Inc. announced that the Japan Patent Office has granted 14 claims of the company’s Japanese Patent Application No. 2015-541849, titled “Methods and Compositions for Wound Healing.”
The granted claims provide comprehensive coverage to Imbed’s nanometer-thick polymer multilayer matrix technology, which driven by its nanoscale engineering conforms intimately to the soft tissue, including micro-crevices, of surface wounds or internal organs, and is ultimately bioresorbed. This is a groundbreaking scientific advance that has enabled the realization of the long-held dream of engineering the soft tissue for addressing many healthcare challenges including drug delivery with minimal side effects, preventing surgical site infections, and accelerating the healing of acute and chronic/recalcitrant wounds.
The claims granted cover the nanoscale architecture of polymer multilayer matrix, adjacent polymeric layers and a variety of bioactives—including antimicrobial agents, antibiofilm agents, growth factors, hemostatic agents, peptides, anticoagulant, analgesics, or other drugs—that can be incorporated in the matrix and subsequently delivered to the soft tissue in controlled manner for effective therapeutic action.
Based on this technology, Imbed’s first FDA-cleared product MicroLyte® Ag Matrix is available for over-the-counter and Rx purchase on microlyteag.com. MicroLyte® Ag Matrix not only prevents microbial colonization in fresh wounds but also jumpstarts the healing of persistent chronic wounds that have been non-healing for months and years.
For further information, please contact:
Gaurav Pranami, Ph.D.
Vice President of Research & Development
About Imbed Biosciences, Inc.
Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented MicroLyte® matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.www.imbedbio.com, www.MicroLyteAg.com, facebook.com/imbedbio, or @MicroLyteAgMtrx on twitter.